Introducing the Drug Exclusivity Dashboard
October 19, 2024
Drug exclusivity is an important metric to track when monitoring pharma portfolios. RxDataLab has created a dashboard to monitor estimated drug patent and exclusivity expiration in the US.
Scientific Analysis of Biotechnology Companies
Technical evaluation of therapeutic programs and drug discovery platforms
Most biotech analysts focus on what companies say. We focus on what they do. RxDataLab examines biotechnology companies by analyzing clinical trials, regulatory filings, patents, hiring patterns, and technical documents. Our focus is on therapeutic development programs, devices, and platform technologies – especially those in neuroscience and AI-driven drug discovery.
Recent Analysis
View allA Surge in Investigational New Drug Activity
October 7, 2024
Visualizing the rise in Investigational New Drug (IND) receipts and active INDs during 2019-2020. With no major regulatory changes, the spike appears linked to the COVID-19 pandemic, raising questions about how it shaped drug development.
Essential Datasets for Tracking Drug Development from Discovery to Market
September 27, 2024
The drug development process consists of 5 distinct steps, and there are data sources available to learn more about each step. Here I will cover some of the most important for our work.
Stay Informed
Subscribe for research and analysis on emerging biotechnology and pharmaceutical developments.